Dongwen Lyu

Associate Director of the Target Identification Facility (TIF) in the GCCRI

Dr. Dongwen Lyu (Lv) is an Assistant Professor/Research at UT Health San Antonio. His current research addresses two broad topics. The first topic is to study the cellular and molecular mechanisms of aging and age-related diseases and discover new senolytic drugs which can selectively eliminate senescent cells to treat aging and age-related diseases. The second topic is to study the mechanism of cancers and develop small molecules including covalent and non-covalent inhibitors and proteolysis targeting chimeras (PROTACs) degraders to treat cancers. He has published 42 peer-reviewed papers and serves as an associate editor of Frontiers in Pharmacology. He developed the first generation selective BCL-XL PROTAC degrader (DT2216) and the second generation BCL-xL and BCL-2 dual-degrading PROTAC (753b). DT2216 is currently being investigated as a novel anticancer agent in a Phase-1 clinical trial at Dialectic Therapeutics. Most recently, he led an interdisciplinary team building new assays and finding new E3 ligase ligands to extend the frontiers of targeted protein degradation.

Talks About
#teaching #microsoftoffice

Preferred Locations
#NorthAmerica